How effective is gemcitabine and docetaxel?
With regard to drug administration, the 1-week regimen, in which docetaxel was administered twice at intervals of 1 week (gemcitabine 1,000 mg/m2, D1, D8; docetaxel 35 mg/m2, D1, D8), resulted in a higher response rate of 19% (20/104), while the response rate was 11.7% (13/111) for the 3-week regimen, where docetaxel …
What is gemcitabine and docetaxel?
Gemcitabine-docetaxel (G-D) combination is an effective chemotherapy for patients with advanced soft tissue and bone sarcoma, first developed with G administered on days 1 and 8, and D on day 8 every 21 days and later modified to be administered every 14 days in 2012. The 14-day regimen has become increasingly adopted.
Does uterine sarcoma require chemotherapy?
Surgery to remove the uterus, sometimes along with the fallopian tubes and ovaries and to check the lymph nodes, is the main treatment for all uterine sarcomas. Sometimes this is followed by treatment with radiation, chemotherapy (chemo), or hormone therapy.
What chemotherapy is used for leiomyosarcoma?
Adriamycin (Doxorubicin) and ifosfamide are the chemotherapy drugs that are currently used to treat leiomyosarcoma. They work well for some people, but not everyone. Doctors think that the drugs gemcitabine and docetaxel (Taxotere) may be better.
How long does a person live with uterine sarcoma?
Undifferentiated sarcoma
| SEER Stage | 5-Year Relative Survival Rate |
|---|---|
| Localized | 68% |
| Regional | 36% |
| Distant | 21% |
| All SEER stages combined | 43% |
How long can you live with metastatic leiomyosarcoma?
40 out of every 100 people (40%) with leiomyosarcoma of the trunk survive their cancer for 5 years or more after diagnosis. Around 40 out of every 100 people (around 40%) with leiomyosarcoma of the digestive system survive their cancer for 5 years or more after they are diagnosed.
What is the survival rate of uterine leiomyosarcoma?
Leiomyosarcoma
| SEER Stage | 5-Year Relative Survival Rate |
|---|---|
| Localized | 62% |
| Regional | 34% |
| Distant | 13% |
| All SEER stages combined | 39% |
Can Gemzar® and Taxotere® be used together?
The combination of Gemzar® and Taxotere® has demonstrated effectiveness for treatment of NSCLC, breast cancer, esophageal cancer, and bladder cancers. Researchers believe there might be an additive anti-cancer effect when Gemzar® and Taxotere® are used together.
Is Gemzar effective for soft tissue sarcoma?
According to a recent article published in the Journal of Clinical Oncology, the chemotherapy regimen consisting of Gemzar® (gemcitabine) plus Taxotere® (docetaxel) provides anti-cancer activity in the treatment of soft tissue sarcomas that have stopped responding to previous therapies.
Does gemcitabine have a role in endometrial cancer?
Our findings suggest that gemcitabine shows modest activity in endometrial cancer with a CBR of 39%. The subgroup of patients with clear cell histology treated with gemcitabine displayed a CBR of 71% (5/7 patients) despite having received an average of 3.3 (range, 1-6) prior lines of therapy.
Which chemotherapy regimen is best for soft-tissue sarcoma?
The authors concluded that the chemotherapy regimen consisting of Gemzar® and Taxotere® provides anti-cancer activity in patients with soft-tissue sarcoma that has stopped responding to prior standard therapy.